{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:32:33Z","timestamp":1787311953226,"version":"build-2736575974"},"reference-count":20,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T00:00:00Z","timestamp":1517961600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_raon-2018-0005_s_005\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Malignant mesothelioma (MM) is a rare disease, linked to asbestos exposure in more than 80% of the cases. Matrix metalloproteinases (MMPs) have been identified as modulators of the tumour microenvironment and carcinogenesis. Polymorphisms of selected MMPs have been studied as potential biomarkers of time to progression (TTP) and overall survival (OS) in MM. The aim of our study was to investigate selected MMP polymorphisms as baseline risk predictors in MM development in combination with other well known risk factors, such as asbestos exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2018-0005_s_006\">\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>\n                      The study included 236 patients and 161 healthy blood donors as the control group. Ten different polymorphisms in three MMP genes were genotyped using a fluorescence-based competitive allele-specific assay (KASPar):\n                      <jats:italic>MMP2<\/jats:italic>\n                      rs243865, rs243849 and rs7201,\n                      <jats:italic>MMP9<\/jats:italic>\n                      rs17576, rs17577, rs2250889 and rs20544, and\n                      <jats:italic>MMP14<\/jats:italic>\n                      rs1042703, rs1042704 and rs743257. In statistical analyses continuous variables were described using median and range (25%\u201375%), while frequencies were used to describe categorical variables. Deviation from the Hardy-Weinberg equilibrium (HWE) was assessed using the standard chi-square test. The additive and dominant genetic models were used in statistical analyses. The association of genetic polymorphism with MM risk were examined by logistic regression to calculate odds ratios (ORs) and their 95% confidence intervals (CIs).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2018-0005_s_007\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Carriers of at least one polymorphic\n                      <jats:italic>MMP2<\/jats:italic>\n                      rs243865 allele tended to have a decreased risk for MM (OR = 0.66, 95% CI = 0.44\u20131.00; P = 0.050). The association was more pronounced in patients with known asbestos exposure: carriers of at least one polymorphic allele had significantly lower MM risk (OR = 0.55, 95% CI = 0.35\u20130.86; P = 0.009). None of the other tested polymorphisms showed association with the risk of malignant pleural mesothelioma.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2018-0005_s_008\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The\n                      <jats:italic>MMP2<\/jats:italic>\n                      rs243865 polymorphism may have a protective role in malignant pleural mesothelioma development. This finding is even more evident in patients exposed to asbestos, implying a strong gene-environment interaction.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2018-0005","type":"journal-article","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T18:16:12Z","timestamp":1529000172000},"page":"160-166","source":"Crossref","is-referenced-by-count":13,"title":["Matrix metalloproteinases polymorphisms as baseline risk predictors in malignant pleural mesothelioma"],"prefix":"10.2478","volume":"52","author":[{"given":"Danijela","family":"Strbac","sequence":"first","affiliation":[{"name":"Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Goricar","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine , University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vita","family":"Dolzan","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine , University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viljem","family":"Kovac","sequence":"additional","affiliation":[{"name":"Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2018,2,7]]},"reference":[{"key":"2026082110572583304_j_raon-2018-0005_ref_001","doi-asserted-by":"crossref","unstructured":"Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 2011; 89: 716-24. 10.2471\/BLT.11.086678","DOI":"10.2471\/BLT.11.086678"},{"key":"2026082110572583304_j_raon-2018-0005_ref_002","unstructured":"Cancer in Slovenia 2014. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2017."},{"key":"2026082110572583304_j_raon-2018-0005_ref_003","doi-asserted-by":"crossref","unstructured":"Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141: 52\u201367. 10.1016\/j.cell.2010.03.015","DOI":"10.1016\/j.cell.2010.03.015"},{"key":"2026082110572583304_j_raon-2018-0005_ref_004","doi-asserted-by":"crossref","unstructured":"Rawlings ND, Barrett AJ. Evolutionary families of metallopeptidases. Methods Enzymol 1995; 248: 183-228.","DOI":"10.1016\/0076-6879(95)48015-3"},{"key":"2026082110572583304_j_raon-2018-0005_ref_005","unstructured":"Mineo TC, Ambrogi V. Malignant pleural mesothelioma: factors influencing the prognosis. Oncology (Williston Park) 2012; 26: 1164-75."},{"key":"2026082110572583304_j_raon-2018-0005_ref_006","doi-asserted-by":"crossref","unstructured":"Deraco M, Nonaka D, Baratti D, Casali P, Rosai J, Younan R, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2006; 13: 229-37. 10.1245\/ASO.2006.03.045","DOI":"10.1245\/ASO.2006.03.045"},{"key":"2026082110572583304_j_raon-2018-0005_ref_007","doi-asserted-by":"crossref","unstructured":"\u0160trbac D, Gori\u010dar K, Dol\u017ean V, Kova\u010d V. Matrix metalloproteinases polymorphisms as prognostic biomarkers in malignant pleural mesothelioma. Dis Markers 2017; 2017: 8069529. Epub 2017 Sep 12. 10.1155\/2017\/8069529.","DOI":"10.1155\/2017\/8069529"},{"key":"2026082110572583304_j_raon-2018-0005_ref_008","doi-asserted-by":"crossref","unstructured":"Nan H, Niu T, Hunter DJ, Han J. Missense polymorphisms in matrix metalloproteinase genes and skin cancer risk. Cancer Epidemiol Biomarkers Prev 2008; 17: 3551-7. 10.1158\/1055-9965.EPI-08-0606","DOI":"10.1158\/1055-9965.EPI-08-0606"},{"key":"2026082110572583304_j_raon-2018-0005_ref_009","doi-asserted-by":"crossref","unstructured":"Lin CM, Zeng YL, Xiao M, Mei XQ, Shen LY, Guo MX, et al. The relationship between MMP2 -1306C>T and MMP9 -1562C>T polymorphisms and the risk and prognosis of T-cell acute lymphoblastic leukemia in a Chinese population. Cell Physiol Biochem 2017; 42: 1458-68. 10.1159\/000479210","DOI":"10.1159\/000479210"},{"key":"2026082110572583304_j_raon-2018-0005_ref_010","doi-asserted-by":"crossref","unstructured":"Kova\u010d V, Zwitter M, \u0160trbac D, Gori\u010dar K, Rozman A, Kern I, Rajer M. Cisplatin with pemetrexed or gemcitabine in prolonged infusion for inoperable mesothelioma: a phase II randomized trial. [Abstract]. 17th World Conference on Lung Cancer, 4-7 December 2016, Vienna, Austria. J Thorac Oncol 2017; 12(Suppl 1): S715.","DOI":"10.1016\/j.jtho.2016.11.1929"},{"key":"2026082110572583304_j_raon-2018-0005_ref_011","unstructured":"National Institute of Environmental health Sciences. SNP Function Prediction (Func Pred). [Internet]. Available at https:\/\/snpinfo.niehs.nih.gov\/snpinfo\/snpfunc.html. Accessed 15 Jan 2017."},{"key":"2026082110572583304_j_raon-2018-0005_ref_012","doi-asserted-by":"crossref","unstructured":"Wang J, Cai Y. Matrix metalloproteinase 2 polymorphisms and expression in lung cancer: a meta-analysis. Tumour Biol 2012; 33: 1819-28. 10.1007\/s13277-012-0441-0","DOI":"10.1007\/s13277-012-0441-0"},{"key":"2026082110572583304_j_raon-2018-0005_ref_013","doi-asserted-by":"crossref","unstructured":"Hu C, Wang J, Xu Y, Li X, Chen H, Bunjhoo H, et al. Current evidence on the relationship between five polymorphisms in the matrix metalloproteinases (MMP) gene and lung cancer risk: a meta-analysis. Gene 2013; 517: 65-71. 10.1016\/j.gene.2012.12.085","DOI":"10.1016\/j.gene.2012.12.085"},{"key":"2026082110572583304_j_raon-2018-0005_ref_014","doi-asserted-by":"crossref","unstructured":"Tao L, Li Z, Lin L, Lei Y, Hongyuan Y, Hongwei J, et al. MMP1, 2, 3, 7, and 9 gene polymorphisms and urinary cancer risk: a meta-analysis. Genet Test Mol Biomarkers 2015; 19: 548-55. 10.1089\/gtmb.2015.0123","DOI":"10.1089\/gtmb.2015.0123"},{"key":"2026082110572583304_j_raon-2018-0005_ref_015","doi-asserted-by":"crossref","unstructured":"Wieczorek E, Reszka E, Jablonowski Z, Jablonska E, Beata Krol M, Grzegorczyk A, et al. Genetic polymorphisms in matrix metalloproteinases (MMPs) and tissue inhibitors of MPs (TIMPs), and bladder cancer susceptibility. BJU Int 2013; 112: 1207-14. 10.1111\/bju.12230","DOI":"10.1111\/bju.12230"},{"key":"2026082110572583304_j_raon-2018-0005_ref_016","doi-asserted-by":"crossref","unstructured":"Sherry ST, Ward MH, M. Kholodov, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001; 29: 308-11.","DOI":"10.1093\/nar\/29.1.308"},{"key":"2026082110572583304_j_raon-2018-0005_ref_017","doi-asserted-by":"crossref","unstructured":"Tunesi S, Ferrante D, Mirabelli D, Andorno S, Betti M, Fiorito G, et al. Gene-asbestos interaction in malignant pleural mesothelioma susceptibility. Carcinogenesis 2015; 36: 1129-35. 10.1093\/carcin\/bgv097","DOI":"10.1093\/carcin\/bgv097"},{"key":"2026082110572583304_j_raon-2018-0005_ref_018","doi-asserted-by":"crossref","unstructured":"Franko A, Kotnik N, Goricar K, Kovac V, Dodic-Fikfak M, Dolzan V. The influence of genetic variability on the risk of developing malignant mesothelioma. Radiol Oncol 2018; 52: 105-111. doi: 10.1515\/raon-2018-0004","DOI":"10.2478\/raon-2018-0004"},{"key":"2026082110572583304_j_raon-2018-0005_ref_019","doi-asserted-by":"crossref","unstructured":"Neri M, Filiberti R, Taioli E, Garte S, Paracchini V, Bolognesi C, et al. Pleural malignant mesothelioma, genetic susceptibility and asbestos exposure. Mutat Res 2005; 592: 36-44. 10.1016\/j.mrfmmm.2005.06.003","DOI":"10.1016\/j.mrfmmm.2005.06.003"},{"key":"2026082110572583304_j_raon-2018-0005_ref_020","doi-asserted-by":"crossref","unstructured":"Franko A, Dol\u017ean V, Arneri\u0107 N, Dodi\u010d-Fikfak M. The influence of gene-gene and gene-environment interactions on the risk of asbestosis. Biomed Res Int 2013; 2013: 405743. 10.1155\/2013\/405743","DOI":"10.1155\/2013\/405743"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/content.sciendo.com\/view\/journals\/raon\/52\/2\/article-p160.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2018-0005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:57:35Z","timestamp":1787309855000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2018-0005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,7]]},"references-count":20,"aliases":["10.1515\/raon-2018-0005"],"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2,7]]},"published-print":{"date-parts":[[2018,2,7]]}},"alternative-id":["10.2478\/raon-2018-0005"],"URL":"https:\/\/doi.org\/10.2478\/raon-2018-0005","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,7]]}}}